SAN FRANCISCO, Nov. 2, 2010 /PRNewswire/ — Deloitte
released a new report, “Innovative Strategies for Oncology Drug
Development,” highlighting specific drug development approaches
that have enabled biotech companies to produce a substantial number
of first-in-class compounds and more than $1 billion in oncology
drugs while transforming the medical outlook for many cancer
patients.
“Scientific innovation has brought measurable rewards such as
reduced development times, higher success rates for cancer drugs,
and increased investment and activity across the biopharmaceutical
industry,” said Lisa Natanson, senior analyst, Deloitte Recap LLC.
“We see clear patterns of successful drug development from this
study of a defined set of biotechnology companies that have
produced innovative cancer drugs in the last decade.”
By analyzing the drug development patterns of the Deloitte
Recap BioPortfolio Index (RBI) companies, a select group of
more than 150 biotechnology companies that have been tracked and
benchmarked for more than a decade, Deloitte identified the
following key findings:
- FDA-approved oncology compounds all heavily utilized at least
one (and some as many as four) special U.S. regulatory mechanisms,
such as Fast Track designation, Orphan Drug status, or Accelerated
Approval, to speed clinical development and reduce FDA transit
times. - Orphan indications served as an initial market entry point to
billion dollar markets followed by label expansion efforts to
broaden the patient populations. - Innovative agents, such as those targeting receptor tyrosine
kinases, achieved up to 31 percent approval success rates.
“Overall, the findings of this report demonstrate that the
biotech industry is having a measurable impact on developing new
therapies in the ‘war on cancer,'” concluded Matthew Hudes,
national managing principal of the biotechnology practice for
Deloitte Co
‘/>”/>